DonaldECutlipMD
Cardiology • Boston, MAInterventional Cardiology
Professor of Medicine, Beth Israel Deaconess Medical Center
Dr. Cutlip is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Beth Israel Deaconess Med Ctr
330 Brookline Ave Es217
Boston, MA 02215Phone+1 617-667-7455Fax+1 617-632-7460
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1992 - 1996
University of ConnecticutResidency, Internal Medicine, 1979 - 1983
University of South Florida College of MedicineClass of 1979
Certifications & Licensure
MA State Medical License 1993 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions Start of enrollment: 2004 Apr 01
- Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization. Start of enrollment: 2007 Jan 01
- EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 1368 citationsTwelve or 30 months of dual antiplatelet therapy after drug-eluting stents.Laura Mauri, Dean J. Kereiakes, Robert W. Yeh, Priscilla Driscoll-Shempp, Donald E. Cutlip
The New England Journal of Medicine. 2014-12-03 - 1960 citationsStenting versus Endarterectomy for Treatment of Carotid-Artery StenosisThomas G. Brott, Robert W. Hobson, George Howard, Gary S. Roubin, Wayne M. Clark
The New England Journal of Medicine. 2010-06-30 - 4495 citationsClinical End Points in Coronary Stent Trials A Case for Standardized DefinitionsDonald E. Cutlip, Stephan Windecker, Roxana Mehran, Ashley B Boam, David J. Cohen
Circulation. 2007-05-01
Journal Articles
- Original Investigations Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents: BIOFLOW V 2-Year ResultsDavid E Kandzari, Ron Waksman, Donald E Cutlip, Elie G Gharib, ScienceDirect
- Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus DocumentWilliam F Fearon, John Spertus, Roxana Mehran, Donald Cutlip, Gregg W Stone, Mitchell W Krucoff, European Heart Journal
Authored Content
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsMarch 2017
Press Mentions
New Biomarker-Based Risk Score Performs Well in ACSOctober 25th, 2022- Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?December 2nd, 2020
- Making Sense of MI: EXCEL and SYNTAX Tackle Event DefinitionsSeptember 28th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
